Citation Impact
Citing Papers
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
2002 Standout
ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.
2001
Intratumor microvessel density as a prognostic factor in cancer.
1995
Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer
2004
Untangling the ErbB signalling network
2001 Standout
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
1997
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
2009 Standout
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.
1994
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
1995
Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma
2003 StandoutNobel
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
1999 Standout
Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer
1999
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Why do cancers have high aerobic glycolysis?
2004 Standout
HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas
2005 StandoutNobel
Criteria for prognostic factors and for an enhanced prognostic system
1993
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Expression of hypoxia-inducible factor 1: mechanisms and consequences
2000 StandoutNobel
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
2007 Standout
Role of Gemcitabine in Breast Cancer Management: An Update
2006
Growth Regulated Oncogene-α expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC Receptor-2 dependent mechanism
2000
Head and neck cancer
2008 Standout
Therapies directed at vascular endothelial growth factor
2002
Gestational trophoblastic disease
2010 Standout
Prognostic factors in early breast carcinoma
1994
Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis
1999
Angiogenesis and metastasis
1996
Scleroderma
2009 Standout
Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study
1997
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
2011 Standout
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Putting tumours in context
2001 Standout
Blinded by the Light: The Growing Complexity of p53
2009 Standout
Regulation of Hypoxia-Inducible Factor-1α, Vascular Endothelial Growth Factor, and Angiogenesis by an Insulin-Like Growth Factor-I Receptor Autocrine Loop in Human Pancreatic Cancer
2003 StandoutNobel
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Clinical Applications of Research on Angiogenesis
1995 Standout
Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma
1996
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
2005 Standout
Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial
1997
Hyperplasia of dermal microvascular pericytes in scleroderma*
2004
Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas
2002
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
The tumor microenvironment and its role in promoting tumor growth
2008 Standout
Microtubules as a target for anticancer drugs
2004 Standout
Protein tyrosine kinases and cancer
1997
HIF-1α, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors
2002 StandoutNobel
The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients
1994
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome
2007
Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and theor relation to estradiol receptor (ER) status
1997
Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients
1996
p53 Mutation and Locoregional Treatment Failure in Head and Neck Squamous Cell Carcinoma
1996
Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas
2000
Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx Carcinoma
1999 Standout
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
1998 Standout
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
2006 Standout
Anemia of Chronic Disease
2005 Standout
Sequence and structure-based prediction of eukaryotic protein phosphorylation sites
1999 Standout
Head and Neck Cancer
2001 Standout
Phase I Study of Vinorelbine and Docetaxel with Granulocyte Colony-Stimulating Factor Support in the Treatment of Metastatic Breast Cancer
2002
Drug Resistance and the Solid Tumor Microenvironment
2007 Standout
Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas
1996
Fatty Acid Synthase (Fas) Predictive Strength in Poorly Differentiated Early Breast Carcinomas
1999
The Complex Role of Estrogens in Inflammation
2007 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
2001 Standout
Monotherapy options in the management of metastatic breast cancer
2003
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Immunohistochemical analysis of integrin αvβ3 expression on tumor‐associated vessels of human carcinomas
1997
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
2002 Standout
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
1999 Standout
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
2000
HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression
2001 StandoutNobel
An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer
2002 Standout
Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer
2002
p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma
2000
Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8
2000
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
1998 StandoutScience
Doppler ultrasonography of the uterine artery and the response to chemotherapy in patients with gestational trophoblastic tumors.
2002
Angiogenesis Ischemic and Neoplastic Disorders
2003 StandoutNobel
Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
2006
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma
2001 StandoutNobel
Regulation of Mammalian O2Homeostasis by Hypoxia-Inducible Factor 1
1999 StandoutNobel
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
1998
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
2002 Standout
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
2007 Standout
Angiogenesis and Tumor Metastasis
1998
Hypoxia Induces Proteasome-Dependent Degradation of Estrogen Receptor α in ZR-75 Breast Cancer Cells
2002
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Works of Alessandro Testolin being referenced
Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
1994
Intratumoral microvessel density and L53 protein: Correlation with metastasis in head‐and‐neck squamous‐cell carcinoma
1993
Vinorelbine in pre-treated advanced head & neck squamous cell carcinoma
1994
Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.
1992
Synchronous Radiotherapy and Chemotherapy with Cisplatin in the Management of Locally Advanced or Recurrent Head and Neck Cancer
1992
Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy.
1995
TREATMENT OF LOCALLY ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK WITH CONCURRENT RADIOCHEMOTHERAPY - RANDOMIZED COMPARISON OF CISPLATIN VERSUS CARBOPLATIN
1993